Imagine a world where millions could avoid the dreaded colonoscopy—a procedure that, while life-saving, is invasive, time-consuming, and often anxiety-inducing. What if a simple 90-second test could revolutionize bowel cancer detection, sparing countless patients from unnecessary discomfort? This isn’t science fiction; it’s the promise of the Oricol test, a groundbreaking innovation that could transform how we approach one of the UK’s deadliest cancers. But here’s where it gets controversial: could this test really replace the gold standard colonoscopy, or are we risking accuracy for convenience? Let’s dive in.
Developed by Cambridge-based Origin Sciences, the Oricol test uses a cutting-edge ‘triomic’ approach to assess three critical factors: genetic mutations, epigenetic markers that control gene activity, and bacteria linked to early cancer development. In a study of 800 patients in Shropshire, soon to be published in Nature Communications, the test accurately distinguished between healthy individuals and those with bowel cancer. It even detected polyps—precursors to cancer—earning it the nickname ‘biological tape recorder.’
Here’s how it works: administered by a nurse at a community center, the test involves inserting a small syringe into the rectum, briefly inflating a balloon, and then analyzing the sample in a lab. While it can’t definitively diagnose bowel cancer, it can rule out the disease in 80% of patients with worrying symptoms. Those with positive results still need a colonoscopy, but for the majority, this means avoiding the more invasive procedure altogether.
And this is the part most people miss: if larger studies, expected next year, confirm its accuracy, the Oricol test could slash NHS colonoscopy numbers by at least 600,000 annually. That’s a massive reduction in costs—saving the NHS up to £720 million a year—and a huge relief for patients. Bowel cancer affects nearly 44,000 people in the UK annually, killing 17,500, and the current diagnostic process is both expensive (£800-£1,200 per colonoscopy) and time-consuming.
Take Parminder Dhani, 65, from Telford, who participated in the Oricol trial after experiencing stomach pain. The test was ‘quick, easy, and comfortable,’ she said. A follow-up colonoscopy confirmed bowel cancer, and she was swiftly referred for surgery. ‘It all happened really quickly,’ she noted, highlighting the test’s potential to expedite treatment.
But not everyone is convinced. Critics argue that relying on a new test could lead to missed diagnoses, especially since colonoscopies remain the gold standard. Is it worth trading some certainty for convenience? Jon Lacy-Colson, a colorectal surgeon at Shrewsbury and Telford Hospital NHS Trust, counters that only 4% of patients who undergo colonoscopies actually have cancer, while 80% have no serious issues. For them, the Oricol test could be a game-changer.
The test’s impact could extend beyond diagnostics. Hugo Lywood, CEO of Origin Sciences, envisions using it to screen for multiple cancers simultaneously and improve the NHS’s bowel cancer screening program. Currently, the at-home stool test detects just 10% of cases due to its low sensitivity. With Oricol as an interim step, Lywood believes this could jump to 60%. But could this lead to over-testing, or is it the key to catching cancer earlier?
Lord Prior of Brampton, former chairman of NHS England, is optimistic. ‘It could make a massive difference to patient outcomes and diagnostic costs,’ he said. Yet, the legacy of cases like Deborah James—the ‘BowelBabe’ blogger who died at 40 after delayed diagnosis—reminds us of the urgent need for better, faster solutions.
As Jo Williams, CEO of Shrewsbury and Telford Hospital NHS Trust, puts it, ‘This test could revolutionize colon cancer diagnostics, making the process more comfortable and efficient.’ But the question remains: are we ready to embrace this change? What do you think? Could the Oricol test be the future of cancer screening, or are we moving too fast? Share your thoughts in the comments—let’s spark a conversation that could shape the future of healthcare.
